Clinical trials: Symptoms, Behavioral
Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)
The purpose of the study is to explore the Tolerability and Safety of the H-Coil deep Transcranial Magnetic Stimulation (TMS) in combination with Serotonin Selective Reuptake Inhibitor (SSRI) for Subjects with Major Depression…
- Trial name
- NCT01361815
- Testing
- H-Coil Deep TMS in combination with SSRIs
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 75 people
- Sponsor
- Brainsway
Patient Engagement, COVID-19
Collaborative Open Research Initiative Study (CORIS-1)
The Collaborative Open Research Initiative Study (CORIS) is a groundbreaking international research endeavor aimed at exploring vital topics within the field of health professions education.
- Conditions
- Patient Engagement, COVID-19, Preventable Disease, Vaccine, Burnout, Professional
- Trial name
- CORIS-1 (NCT06357650)
- Testing
- No intervention. This is an observational study
- Volunteers
- 15,000 people
- Sponsor
- Chisquares Incorporated
Depression, Bipolar Disorder
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.
- Trial name
- NCT03403790
- Testing
- Quetiapine
- Where
- 47 sites in Japan
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
ASD
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With Autism
Mental Imagery Therapy for Autism (MITA) is a highly innovative adaptive language therapy application for children with autism. MITA exercises are limitless in variations, therefore avoiding routinization.
- Trial name
- MITA-RCT (NCT07326423)
- Testing
- Mental Imagery Therapy for Autism (MITA), General executive function
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- ImagiRation, LLC
Suicide
CAMS Relational Agent System (CAMS-RAS) for Suicide Prevention
This Phase II study is a continuation of the Phase I feasibility study where the investigators fully met and exceeded project aims to design, build, and test the usability and acceptability of an avatar-based system, Jaspr Health…
- Trial name
- V-CAMS (NCT03584386)
- Testing
- Jaspr, Jaspr-at-Home (JAH)
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Pulmonary Disease, Chronic Obstructive
Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with…
- Trial name
- NCT04795323
- Testing
- TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Stress, Psychological, Loneliness
Ecological Momentary Assessment and Text Message Intervention for Stress Management
Feasibility and acceptability of an Ecological Momentary Assessment (EMA) compared with an EMA plus automated text message intervention for stress management
- Conditions
- Stress, Psychological, Loneliness, Covid19, Stress
- Trial name
- NCT04907942
- Testing
- EMA + EMA and FACE Stress, EMA Alone
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Click Therapeutics, Inc.
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Depressive Disorder
Seasonal Affective Depression (SAD) Study
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
- Trial name
- NCT00069459
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Agitation,Psychomotor, Disruptive Behavior
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of…
- Conditions
- Agitation,Psychomotor, Disruptive Behavior, Dementia, Alzheimer Disease
- Trial name
- NCT06217146
- Testing
- Medical Cannabis
- Where
- 3 sites in Israel
- Volunteers
- 24 people
- Sponsor
- M. H MediCane Ltd.
Depression, Panic Disorder
Special Investigation Of Long Term Use Of Sertraline.
Special investigation of long term use of sertraline, 52 Week Observation, Long-Term Safety. The objective of this "Special investigation" is to collect information about 1) adverse drug reactions not expected from the LPD…
- Trial name
- NCT00605813
- Testing
- Sertraline hydrochloride
- Volunteers
- 542 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Oral Mucositis, Quality of Life
Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.
The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- STOPOMP (NCT05635929)
- Testing
- XCM-OM118 Composition comprising olive oil, betaine and xylitol
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- Mucosa Innovations, S.L.
Weight Loss, Behavior, Health
Mobile Behavior Change Program for Weight Loss in Breast Cancer Survivors
The purpose of this study is to evaluate the preliminary efficacy of a Noom Breast Cancer Weight Loss Program on weight loss outcomes, quality of life, and physical activity.
- Trial name
- NCT04753268
- Testing
- Noom Healthy Weight Program
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Dementia
Fasudil fOr redUcing elopemeNt and Spatial Disorientation
Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating.
- Trial name
- FOUND (NCT04793659)
- Testing
- Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day
- Where
- 11 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Woolsey Pharmaceuticals
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With MDD
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03560518
- Testing
- Rapastinel
- Where
- 40 sites in United States
- Volunteers
- 439 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
- Trial name
- NCT05385783
- Testing
- CYB003, Psychotherapy, Psychological Support
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cybin IRL Limited
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
Creatine Deficiency, X-linked
Observational Study of Males With Creatine Transporter Deficiency
The objectives of this study are to illustrate the clinical, neuro/electrophysiologic, biochemical, and developmental status and progression of patients with Creatine Transporter Deficiency (CTD) and to evaluate the utility of…
- Trial name
- Vigilan (NCT02931682)
- Where
- 10 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Major Depressive Disorder
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.
- Trial name
- EXTEND (NCT06605105)
- Testing
- CYB003
- Where
- 49 sites in United States, Australia and 3 more
- Volunteers
- 468 people
- Sponsor
- Cybin IRL Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.